Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04914078
Other study ID # 82/2021/Oss/AOUFe - ESAMBIO
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 21, 2021
Est. completion date December 1, 2023

Study information

Verified date May 2022
Source Università degli Studi di Ferrara
Contact Marco Contoli, MD
Phone +390532688148
Email ctm@unife.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a hypothesis-generating project to investigate a) infective etiology and b) inflammatory profile of the exacerbations of asthma in severe asthmatic patients treated with the humanized monoclonal antibody against interleukin-5 Mepolizumab. Under these treatment conditions the study will inform on the relationship between these two axes: infection & innate immunity Vs inflammatory profile changes occurring during exacerbation events. In addition, the study will also explore the effect of Mepolizumab treatment on airway microbial composition and on airway/systemic immune response both at stable state and at the exacerbation.


Description:

Longitudinal, observational study to evaluate the infective etiology and the inflammatory profile of asthma exacerbations in severe asthmatic patients treated (as part of routine medical care) with the humanized monoclonal antibody against interleukin-5 Mepolizumab. The participants receive Mepolizumab as part of routine medical care (see inclusion criteria). The study will assess the effect of the intervention (Mepolizumab) on airway microbial compositions and on airway/systemic inflammation at exacerbation and at stable state. The patients will be evaluated at baseline (the day of Mepolizumab initiation, before Mepolizumab administration - V0), at 1 month after Mepolizumab initiation (treatment visit - V1), at exacerbation (exacerbation visit - V2) and at 3 months after the exacerbation event (convalescence visit - V3) up to 12-month study period (Table 1). To perform the convalescence visit, a 3-month extension of the study period will be applied if the exacerbation occurs from month 9 to month 12 from the initiation of Mepolizumab. Recurrent exacerbation events will be evaluated separately when a paired-3-month convalescence visit can be performed within the study period. The patients will contact the center/researchers in case of worsening of the respiratory symptoms to schedule the exacerbation visit. The visit will be performed within 7 days from the beginning of the deterioration of the symptoms. At each visit, the following procedures will be performed in all the patients: 1) Clinical/pharmacological assessment (including assessment of asthma control; and measurements of central and peripheral fractional exhaled nitric oxide); 2) lung function tests (including lung volumes evaluation and small airway functional assessment by impulse oscillometry - IOS); 3) blood and sputum differential inflammatory cell counts; 4) sputum samples for microbiological assays (conventional sputum cultures and Multiplex Real Time PCR for virus and bacterial detection); 5) blood and sputum samples for cytokine profiling. In a representative subgroup of patients (n=30) breath condensate, blood and sputum samples will be performed for: 1) airway microbiome (16S ribosomal RNA Sequencing) evaluation; 2) blood innate immune responses; 3) transcriptomics and proteomics of sputum inflammatory cells; 4) breathomics. The study has been submitted for approval to the ethics committee, and informed written consent will be obtained from each enrolled subject.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility The cohort of patients included in the study will consist of severe asthmatic patients receiving Mepolizumab as part of routine medical care, i.e. eligible for Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco). The patients will receive Mepolizumab treatment irrespective of the enrollment in the study but because of the clinical indication. Inclusion criteria: - severe asthmatic patients according to GINA document (Step 4 and 5 GINA) - blood eosinophilic count above 300 cells/mcl at least once in the previous year and =150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. - In addition, one of the following conditions will be required: 1) =2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year. Exclusion criteria: - COPD - Active smoking - Chronic interstitial lung diseases - Systemic corticosteroid/immunosuppressive treatments for concomitant conditions other than asthma

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mepolizumab 100 MG
The patients will treated with subcutaneous Mepolizumab at 100 mg every 30 days. Patients will be recruited among those eligible to Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco) guidelines who will accept to participate to the study. In particular inclusion criteria will be: severe (Step 4 and 5 GINA) asthma with at least blood eosinophilic count above 300 cells/mcl at least once in the previous year and =150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. In addition, one of the following conditions will be required: 1) =2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.

Locations

Country Name City State
Italy Azienda Ospedaliero Universitaria Ferrara Ferrara

Sponsors (2)

Lead Sponsor Collaborator
Università degli Studi di Ferrara GlaxoSmithKline

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Inflammation Co-primary measurements will be: i) changes in blood and sputum eosinophil counts at exacerbation compared to stable state 1 year
Primary Infections Co-primary measurements will be: ii) changes in the frequency of microbial agent detection in sputum samples at exacerbation compared to stable state. 1 year
Secondary Lung function FEV1 l FEV1 litre 1 year
Secondary Lung function FEV1 % FEV1% predicted 1 year
Secondary Lung function FVC l FVC litre 1 year
Secondary Lung function FVC % FVC % predicted 1 year
Secondary Lung function VC l vital capacity (VC) litre 1 year
Secondary Lung function VC % vital capacity (VC) % predicted 1 year
Secondary Lung function - Impulsed Oscillometry kPa R5-R20 (kPa/L/s) 1 year
Secondary Lung function - Impulsed Oscillometry % R5-R20 % predicted 1 year
Secondary Asthma control questionnaire (ACT) Score ranging from 5 to 25 1 year
Secondary Fractional exhaled nitric oxide (FeNO) parts per billions (ppb) in the exhaled breath 1 year
Secondary Sputum Quantitative bacteriology Serial dilutions (up to 10-12) of sputum samples will be made and cultured on the appropriate media. Colony- forming units (CFU)/mL will be calculated. 1 year
Secondary Sputum virus profiling The commercially available multiplex PCR assay RespiFinder RGĀ® (Qiagen) was used according to manufacture instructions for the simultaneous detection and differentiation of 21 respiratory pathogens, including both viruses and atypical bacteria 1 year
Secondary Cytokines cytokines profiling (Th1/Th2/Th17 - pg/ml) in blood serum and sputum supernatants will be assessed by by multiplex immunoassay-based (EMD Millipore Burlington, MA, USA) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05018299 - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma Phase 2
Recruiting NCT05472324 - Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. Phase 2
Completed NCT05576454 - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects Phase 1
Recruiting NCT04520165 - Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Not yet recruiting NCT04463836 - Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
Enrolling by invitation NCT06421402 - K-HEALTH in AIR - Barcelona Pilot - Cohort
Recruiting NCT03377920 - Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's. N/A
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Recruiting NCT04045587 - International Severe Asthma Registry: Canadian Cohort
Completed NCT05616338 - Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC) N/A
Active, not recruiting NCT02038374 - Clinico-biological Correlation of Severe Asthma in Children N/A
Active, not recruiting NCT02114034 - Cohort Analysis of Clinical and Biological Severe Childhood Asthma
Recruiting NCT06035289 - Register Schweres Asthma - German Asthma Net e.V.
Not yet recruiting NCT03532685 - Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up N/A
Completed NCT03931954 - Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Recruiting NCT03984253 - Swiss Severe Asthma Register
Recruiting NCT03435237 - Phenotyping Asthma for Bronchial Thermoplasty
Recruiting NCT03476109 - Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. Phase 4
Active, not recruiting NCT06389058 - Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System